A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination
- 1 June 2001
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (12) , 921-929
- https://doi.org/10.1038/sj.gt.3301477
Abstract
Recent work highlights the potential usefulness of MVM-based vectors as selective vehicles for cancer gene therapy (Dupont et al, Gene Therapy, 2000; 7: 790–796). To implement this strategy, however, it is necessary to develop optimized methods for producing high-titer, helper-free parvovirus stocks. Recombinants of MVMp (rMVMp) are currently generated by transiently co-transfecting permissive cell lines with a plasmid carrying the vector genome and a helper plasmid expressing the capsid genes (replaced with a foreign gene in the vector genome). The resulting stocks, however, are always heavily contaminated with replication-competent viruses (RCV), which precludes their use in vivo and particularly in gene therapy. In the present work we have developed a second-generation MVMp-based vector system specifically designed to reduce the probability of RCV generation by homologous recombination. We have constructed a new MVMp-based vector and a new helper genome with minimal sequence overlap and have used the degeneracy of the genetic code to further decrease vector–helper homology. In this system, the left homologous region was almost completely eliminated and the right sequence overlap was reduced to 74 nt with only 61% homology. We were thus able to substantially reduce ( ∼ 200 ×), but not completely eliminate, generation of contaminating viruses in medium-scale rMVMp preparations. Since the remaining sequence homology between the new vector and helper genomes is weak, our results suggest that contaminating viruses in this system are generated by nonhomologous recombination. It is important to note, unlike the autonomously replicating helper viruses produced from the first-generation vector/helper genomes, the contaminating viruses arising from the new packaging system cannot initiate secondary infection rounds (so they are not ‘replication-competent viruses’). Our findings have important implications for the design of new MVMp-based vectors and for the construction of trans-complementing packaging cell lines.Keywords
This publication has 43 references indexed in Scilit:
- Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vectorGene Therapy, 2000
- Highly Efficient Transduction and Expression of Cytokine Genes in Human Tumor Cells by Means of Autonomous Parvovirus Vectors; Generation of Antitumor Responses in Recipient MiceHuman Gene Therapy, 2000
- cis Requirements for the Efficient Production of Recombinant DNA Vectors Based on Autonomous ParvovirusesHuman Gene Therapy, 1999
- Influence of Sequence and Size of DNA on Packaging Efficiency of Parvovirus MVM-Based VectorsHuman Gene Therapy, 1999
- Characterization of Replication-Competent Adenovirus Isolates from Large-Scale Production of a Recombinant Adenoviral VectorHuman Gene Therapy, 1999
- Lack of a detectable effect of capsid proteins on the cell-dependent activity of parvovirus MVMp promotersResearch in Virology, 1994
- Recombinant LuIII Autonomous Parvovirus as a Transient Transducing Vector for Human CellsHuman Gene Therapy, 1993
- Retrovirus Packaging CellsHuman Gene Therapy, 1990
- Lymphokine gene therapy for cancerImmunology Today, 1990
- An Escherichia coli recBCsbcBrecF host permits the deletion-resistant propagation of plasmid clones containing the 5'-terminal palindrome of minute virus of miceGene, 1985